Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
Pharmaceutical Technology17h
Novo Nordisk earmarks $2bn for Chinese “triple G” weight loss shot
Novo Nordisk has acquired the global rights to United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal ...
pharmaphorum18h
UK weight loss market: M&A opportunities
Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an additional 38% considered overweight. This epidemic not only impacts individual ...
FINAL REMINDER NVO DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Novo Nordisk A/S Investors to Participate in the Class Action Lawsuit
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors ...
Trump Tariff Uncertainty Will Break This Stock Market Calm, Brace for Another Storm. And 5 Other Things to Know Today.
Tesla bounces back amid autonomous driving hope, United Airlines hikes card and lounge fees, and more news to start your day.
SAP Overtakes Novo to Become Europe’s Biggest Stock
The pivot to the cloud has led to a big rally in SAP stock.